



Vaccines and Global Health: The Week in Review
29 January 2022 :: Issue 641
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

::

[Milestones - Perspectives](#)

:: *[Coronavirus \[COVID-19\] - WHO](#)*

:: *[Emergencies](#)*

:: *[Organization Announcements](#)*

:: *[Journal Watch](#)*

Milestones - Perspectives

.....
.....

WHO - 150th session of the Executive Board

24 – 29 January 2022

Main Documents *[Selected]*

Resolutions *[Selected]*

EB150.R3

The global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections

Decisions *[Selected]*

EB150(4)

Political declaration of the third high-level meeting of the General Assembly on the prevention and control of noncommunicable diseases

Conf Papers *{ Selected }*

EB150/CONF./1

Global strategy and plan of action on public health, innovation and intellectual property

Draft decision proposed by Argentina, Bangladesh, Brazil, Colombia, Costa Rica, Ecuador, India, Indonesia, Kenya, Peru, Portugal, South Africa and Uruguay

EB150/CONF./2 Rev.1

Standing Committee on Health Emergency (Pandemic) Prevention, Preparedness and Response

Draft decision proposed by Australia, Austria, Belgium, Canada, Denmark, France, Germany, Japan, Slovenia, Switzerland and United States of America

EB150/CONF./3

Strengthening of the International Health Regulations (2005) through a process for revising the regulations through potential amendments

Draft decision proposed by Albania, Australia, Canada, Colombia, India, Japan, Monaco, Montenegro, Norway, Peru, Republic of Korea, United Kingdom of Great Britain and Northern Ireland, United States of America, Uruguay and Member States of the European Union

Statements by non-State actors in official relations with WHO at the WHO governing bodies meetings

- 150th EB Constituency Statements
- 150th EB Individual Statements

.....
.....

European Health Union: new rules to improve clinical trials in the EU

Statement 28 January 2022

As of Monday 31 January, the assessment and supervision of clinical trials throughout the EU will be harmonised, notably via a Clinical Trials Information System (CTIS) run by the European Medicines Agency. On this date the Regulation on Clinical Trials will enter into application. This Regulation will improve conducting clinical trials in the EU, with the highest standards of safety for participants and increased transparency of trial information.

Welcoming this important step, European Commissioner for Health and Food Safety, Stella Kyriakides, made the following statement: "The Clinical Trials Regulation marks an important and positive step for European patients and brings us closer to a stronger European Health Union. It will allow us to have swifter authorisation of clinical trials across our Member States, thus improving the efficiency of clinical research as a whole. At the same time, the high quality and safety standards already set for such trials will be upheld. While almost 4000 clinical trials are already carried out each year in the EU, the Regulation will make vital research even more beneficial to the researchers and patients who depend on fast and reliable trials the most.

Over the coming years, the Regulation will create a framework for a more agile clinical trial approval process that will bring Member States closer together in the area of clinical trials. In turn, this will inspire further confidence and trust among citizens, who are at the centre of clinical research. This is why the Regulation is based on the key principle of transparency, allowing for public scrutiny at every step of the way.

Questions and answers on the Regulation

[Excerpt]

2. What changes is the Regulation bringing to clinical trials in the EU?

The Clinical Trials Regulation aims to ensure a greater level of harmonisation of the rules of conducting clinical trials throughout the EU. Key features are:

- A **streamlined application procedure** for all clinical trials conducted in Europe via an online portal (the "Clinical Trials Information System" or CTIS)
- A **single authorisation procedure** for all clinical trials, to allow a fast and thorough assessment by all concerned EU countries
- The **extension of the silent agreement principle**(1) to the authorisation process giving more legal certainty to the organisations or individuals that undertake clinical trials
- **Transparency of clinical trial data** will become the rule. Information on the approval, execution and result of a given clinical trial will be available for the general public.
- **Improvement of the collaboration between Member States on the assessment of unexpected events** occurring in clinical trials, thus assuring the highest standards of safety for participants in European clinical trials. Ultimately, this will lead to an even better understanding of the benefits and the risks of authorised medicinal products.

(1) In the existing legislation, the principle of silent agreement exists only for the assessment by the National Competent Authority. The explicit agreement from an ethics committee was required, even when the timelines foreseen in the legislation were not respected. This led in practice to delays and uncertainties.

.....

European Health Union: a stronger role for the European Medicines Agency

Press release 25 January 2022

Today, as part of the on-going work to build a strong European Health Union, the Council has adopted the Regulation revising the mandate of the European Medicines Agency (EMA), taking an important step towards EMA's reinforcement in crisis preparedness and management for medicinal products and medical devices. **The new rules will allow the Agency to closely monitor and mitigate shortages of medicines and medical devices during major events and public health emergencies and facilitate faster approval of medicines which could treat or prevent a disease causing a public health crisis.** The adoption of a stronger mandate for EMA is part of the European Health Union package proposed by the Commission in November 2020.

Welcoming the adoption today, Vice-President for Promoting our European Way of Life, Margaritis Schinas, said: "Today's adoption marks a milestone for European citizens who have been expecting the EU to put together the tools we need to respond swiftly and efficiently in case of a health crisis. In the past two years, the European Medicines Agency has been a key player in the EU's response to the COVID-19 pandemic, notably in advising, assessing and authorising vaccines and medicines to prevent and treat COVID-19. We promised this to EU citizens and we are delivering!"

Thanks to its reinforced mandate, **the Agency can facilitate a coordinated EU-level response to health crises by:**

- monitoring and mitigating **the risk of shortages** of critical medicines and medical devices;
- **providing scientific advice on medicines** that may have the potential to treat, prevent or diagnose the diseases causing those crises;
- coordinating studies to monitor the **effectiveness and safety of medicinal products** intended to treat, prevent or diagnose diseases related to the public health crisis;
- **coordinating clinical trials** for medicinal products intended to treat, prevent or diagnose diseases related to the public health crisis;
- transferring the expert panels of the Medical Device Regulation to the Agency.

The legislation also formally establishes the Medicines and Medical Devices Shortages Steering Group and the Emergency Task Force, working on the above tasks...

.....
.....

Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits

WHO - 25 January 2022 :: 70 pages

Overview

The objective of the Pandemic Influenza Preparedness Framework is to improve pandemic influenza preparedness and response, and strengthen the protection against the pandemic influenza by improving and strengthening the WHO global influenza surveillance and response system ("WHO GISRS"), with the objective of a fair, transparent, equitable, efficient, effective system for, on an equal footing:

- (i) the sharing of H5N1 and other influenza viruses with human pandemic potential; and
- (ii) access to vaccines and sharing of other benefits.

This Framework applies to the sharing of H5N1 and other influenza viruses with human pandemic potential and the sharing of benefits. This Framework does not apply to seasonal influenza viruses or

other non-influenza pathogens or biological substances that may be contained in clinical specimens shared under this Framework.

This second edition of the Pandemic Influenza Preparedness (PIP) Framework reflects an amendment to Annex 2, Standard Material Transfer Agreement 2, Footnote 1, that was adopted by the Seventy-second World Health Assembly in May 2019. The amendment clarifies that, under certain circumstances, the indirect use of PIP Biological Materials will require the conclusion of an SMTA². The amendment is in effect from the closure of the Seventy-second World Health Assembly (28 May 2019).

[Excerpts]

6.10 Access to vaccines in the inter-pandemic period for developing countries

6.10.1 Separately from measures to support the WHO PIP vaccine stockpile set out in section 6.9 above:

(i) Member States should urge influenza vaccine manufacturers to set aside a portion of each production cycle of vaccines for H5N1 and other influenza viruses with human pandemic potential for stockpiling and/or use, as appropriate, by developing countries; and

(ii) Member States should continue to work with each other, with the Director-General and with influenza vaccine manufacturers, with the aim of ensuring that adequate quantities of vaccines for H5N1 and other influenza viruses with human pandemic potential are made available to developing countries at the same time as to developed countries, on the basis of public health risk and needs and at tiered prices (see 6.12 below).

6.11 Access to pandemic influenza vaccines

6.11.1 Member States should urge vaccine manufacturers to set aside a portion of each production cycle of pandemic influenza vaccine for use by developing countries; and

6.11.2 The Director-General, consulting Member States and the Advisory Group, will convene an expert group to continue to develop international mechanisms, including existing ones, for the production and distribution of influenza vaccines on the basis of public health risk and needs during a pandemic, for consideration by the World Health Assembly in 2010.

...6.13 Technology transfer

6.13.1 The Director-General will continue to work closely with Member States and influenza vaccine manufacturers to implement the WHO Global Pandemic Influenza Action Plan to Increase Vaccine Supply, including its strategies to build new production facilities in developing and/or industrialized countries and through transfer of technology, skills and know-how.

6.13.2 Member States should urge influenza vaccine, diagnostic and pharmaceutical manufacturers to make specific efforts to transfer these technologies to other countries, particularly developing countries, as appropriate.

6.13.3 Technology transfer should be conducted in a manner consistent with applicable national laws and international laws and obligations, facilitated progressively over time, on mutually agreed terms, and be suitable to the capacity of recipient Member States, to empower developing countries to study and manufacture influenza vaccines, diagnostics and pharmaceuticals.

6.13.4 Influenza vaccine manufacturers who receive PIP biological materials may grant, subject to any existing licensing restrictions, on mutually agreed terms, a non-exclusive, royalty-free licence to any influenza vaccine manufacturer from a developing country, to use its intellectual property and other protected substances, products, technology, know-how,

information and knowledge used in the process of influenza vaccine development and production, in particular for pre-pandemic and pandemic vaccines for use in agreed developing countries.

6.13.5 Member States seeking to receive technology to produce influenza vaccine should be encouraged to first conduct studies on the disease burden of seasonal influenza with related economic analysis in their country. Should the study warrant, Member States should be encouraged to consider incorporating seasonal influenza vaccination into their national immunization programme, which will enable sustainable functioning of the manufacturing facilities...

.....
.....

WTO Members discuss way forward in dedicated meeting on WTO pandemic response

27 January 2022

WTO members met on 27 January to discuss the WTO response to the COVID-19 pandemic. The informal meeting convened by the Chair of the General Council, Ambassador Dacio Castillo of Honduras, **looked at issues related to cross-border trade flows and the proposal to waive certain intellectual property protections related to COVID-19 countermeasures.** Director-General Ngozi Okonjo-Iweala called on members to move swiftly to try and reach a comprehensive outcome by the end of February.

The General Council Chair called the meeting following weeks of consultations with delegations on the way forward. **In those conversations, members were of the view that only a holistic, comprehensive and balanced outcome on the WTO pandemic response would be credible.** Delegations expressed willingness and eagerness to continue working on this crucial topic, with the objective of achieving results, and to do so without delay, he said...

The General Council Chair acknowledged the differences between WTO members not only on substance but also on how to carry the discussions forward. Several delegations expressed interest in squaring the circle urgently, while others were more cautious and hesitant to immediately re-engage at this point in time. "But I believe that a path forward can still be found and that these divergences should not stop us from progressing," he said...

DG Okonjo-Iweala thanked members for a "very constructive" discussion in which **all delegations recognized the importance, for the credibility of the WTO, of agreeing on a meaningful pandemic response.** She also noted "the acknowledgement that this demands a holistic approach, both on the side of intellectual property but also on the side of the other trade-related aspects for very sensible reasons, and this is that one cannot move without the other."...

Regarding the small-group discussions on the IP-related aspects of the pandemic response, she asked for members' patience. "This is a very difficult issue. If it were easy, it would have been resolved in the almost two years that this discussion has been going on (in the TRIPS Council). This small group process ... is going on but it is very tough. I have to say there is no easy road."

In conclusion, DG Okonjo-Iweala said: "We should strive to get this result out by the end of February. It will be really sad if this organization keeps talking and debating on this pandemic, and that by the time we come up with a response people will not think it relevant..."

.....
.....

Featured Journal Content

The Lancet

Jan 29, 2022 Volume 399 Number 10323 p411-494, e2

<https://www.thelancet.com/journals/lancet/issue/current>

Health Policy

[Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability](#)

[Suerie Moon, PhD](#) [Jana Armstrong, MBA](#) [Brian Hutler, PhD](#) [Prof Ross Upshur, MD](#) [Rachel Katz, MA](#) [Caesar Atuire, PhD](#) et al. [Show all authors](#)

Published: December 10, 2021

DOI: [https://doi.org/10.1016/S0140-6736\(21\)02344-8](https://doi.org/10.1016/S0140-6736(21)02344-8)

Summary

The Access to COVID-19 Tools Accelerator (ACT-A) is a multistakeholder initiative quickly constructed in the early months of the COVID-19 pandemic to respond to a catastrophic breakdown in global cooperation. ACT-A is now the largest international effort to achieve equitable access to COVID-19 health technologies, and its governance is a matter of broad public importance. We traced the evolution of ACT-A's governance through publicly available documents and analysed it against three principles embedded in the founding mission statement of ACT-A: participation, transparency, and accountability. We found three challenges to realising these principles. First, the roles of the various organisations in ACT-A decision making are unclear, obscuring who might be accountable to whom and for what. Second, the absence of a clearly defined decision making body; ACT-A instead has multiple centres of legally binding decision making and uneven arrangements for information transparency, inhibiting meaningful participation. Third, the nearly indiscernible role of governments in ACT-A, raising key questions about political legitimacy and channels for public accountability. With global public health and billions in public funding at stake, short-term improvements to governance arrangements can and should now be made. Efforts to strengthen pandemic preparedness for the future require attention to ethical, legitimate arrangements for governance.

.....
.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 28 Jan 2022


Confirmed cases :: 364 191 494

Confirmed deaths :: 5 631 457

Vaccine doses administered: 9 854 237 363

.....

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 23 January 2022**



**See [Annex 2: Data, table, and figure notes](#)

Weekly epidemiological update on COVID-19 - 25 January 2022

Overview

Globally, the number of new COVID-19 cases increased in the past week (17-23 January 2022) by 5%, while the number of new deaths remained similar to that reported during the previous week. Across the six WHO regions, over 21 million new cases were reported this week, representing the highest number of weekly cases recorded since the beginning of the pandemic.

Nearly 50 000 new deaths were also reported. As of 23 January 2022, over 346 million confirmed cases and over 5.5 million deaths have been reported worldwide.

A slower increase in case incidence was observed at the global level, with only half of the regions reporting an increase in the number of new weekly cases, as compared to five out of six regions in the previous week. The Eastern Mediterranean Region reported the largest increase in the number of new cases (39%), followed by the South-East Asia Region (36%) and the European Region (13%).

The number of new weekly deaths increased in the South-East Asia Region (44%), the Eastern Mediterranean Region (15%) and the Region of the Americas (7%), while the other Regions all reported declines in new weekly deaths.

In this edition, we provide updates on the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), and summarize their phenotypic characteristics based on available studies. A specific brief update on the Omicron variant, is also provided.

.....

WHO Events

Update on SARS-CoV-2 variant of concern Omicron

1 February 2022 13:30 – 14:30 CET

WHO Public Health Laboratories knowledge sharing webinars - SARS-CoV-2 variants, Emergency Use Listing (EUL) and diagnostics performance monitoring

2 February 2022 11:00 – 12:30 CET

.....

WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

Selected

29 January 2022

Speech

WHO Director-General's closing remarks at the 150th session of the Executive Board – 29 January 2022

24 January 2022

Speech

WHO Director-General's opening remarks at the 150th session of the Executive Board – 24 January 2022

.....
.....

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 23 December 2021

[Full scale view available at title link above]

[No change from 23 December 2021]

.....

COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements

[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca

Press Releases - No new digest announcements identified

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias

Vacunas cubanas muestran altos títulos de neutralización contra ómicron.

Resumen: Las vacunas cubanas han permitido que la COVID-19 en Cuba se comporte de modo diferente al resto del mundo. Las últimas evidencias demuestran altos títulos de neutralización contra la variante ómicron.

28 de Enero, 2022

[Cuban vaccines show high neutralization titers against omicron.

Abstract: Cuban vaccines have allowed COVID-19 in Cuba to behave differently from the rest of the world. The latest evidence shows high neutralization titers against the omicron variant.]

CanSinoBIO

News - *[Website not responding at inquiry]*

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News

January 17, 2022

[CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry](#)

Gamaleya National Center

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China

Home - No new digest announcements identified

Janssen/JNJ

Press Releases - No new digest announcements identified

Moderna

Press Releases

January 27, 2022

[IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology](#)

January 26, 2022

[Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant](#)

Novavax

Press Releases

[Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine](#)

Jan 28, 2022

Pfizer

Recent Press Releases

01.27.2022

[Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment](#)

01.25.2022

[Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age](#)

01.24.2022

[Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant](#)

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

Press releases for media - No new digest announcements identified

Merck

News releases

January 28, 2022

[Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies](#)

Novartis

News

[Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep \(MP0420\), a DARPIn antiviral therapeutic for COVID-19](#)

Jan 10, 2022

SK Biosciences

Press releases - No new digest announcements identified

Valneva

Press Releases

January 25, 2022

[Valneva Advances Booster Phase of Cov-Compare Trial of Its Inactivated COVID-19 Vaccine Candidate](#)

.....

.....

[UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 29 Jan 2022](#)

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]




■■■■■
■■■■■

COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Progress Towards 70% Vaccine Coverage by Mid-2022 1/



Source: IMF and WHO Staff calculations.

1/ Broadly, all countries that are at risk of missing the 70% target by mid-2022 are also below 40% as of early Jan 2022.



Global COVID-19 Access Tracker

<https://www.covid19globaltracker.org/>

Global COVID-19 Access Tracker

The ACT-Accelerator and Multilateral Leaders Task Force Global COVID-19 Access Tracker (GCAT) is a dynamic tool to transparently track progress towards the global targets for access to COVID-19 vaccines, treatments, tests and PPE.

Last Updated on 28 Jan, 2022.

Vaccinations >

56

Countries with vaccination coverage >70%

1,091 Mn

Doses delivered by COVAX to date

Testing >

70

Countries testing daily at rate >100/100k pop

96 Mn

Tests delivered via ACT-A to date

Therapeutics >

--

All cases cared for in all countries (unavailable)

US\$ 170 Mn

Treatments & O2 supplies delivered via ACT-A to date

Health Workers >

--

All healthcare workers protected (unavailable)

US\$ 483 Mn

Personal Protective Equipment (PPE) delivered via ACT-A to date



Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 29 Jan 2022]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)

High income countries: 1 in 1 people, or



67.53%

have been vaccinated with at least one dose as of Jan 26, 2022.

[WHO](#)

Low income countries: 1 in 9 people, or



11.18%

have been vaccinated with at least one dose as of Jan 26, 2022.

[WHO](#)

High income countries have to increase their health care spending by

0.8%

on average to cover cost of vaccinating 70% of the population.

[UNDP Survey, WHO, UNICEF](#)

Low income countries have to increase their health care spending by

56.6%

on average to cover cost of vaccinating 70% of the population.

[UNDP Survey, WHO, UNICEF](#)



Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)


[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.

Donut charts are ordered by proportion of pledged donations shipped.



Data updated on Jan 21st 2022

.....
.....

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

29 Jan 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 364M total confirmed cases; 5.6M total confirmed deaths

Global vaccines administered: 9.99B

Number of Countries: 30

COVAX Allocations Round 4-9 (Number of Doses): 220M

COVAX Delivered (Number of Doses): 310M

Other Delivered (Number of Doses): 340M

Total Delivered (Number of Doses): 650M

Total Administered (Number of Doses): 260M

.....
.....



Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **29 Jan 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).




.....
.....

Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 29 Jan 2022]


- :: [60.9%](#) of the world population has received at least one dose of a COVID-19 vaccine.
- :: [10.04 billion doses](#) have been administered globally, and [24.96 million](#) are now administered each day.
- :: Only [10%](#) of people in low-income countries have received at least one dose.



Share of the population fully vaccinated against COVID-19, Jan 28, 2022

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 29 January 2022, 06:00 (London time)
Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.
OurWorldInData.org/coronavirus • CC BY

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS

News

[HHS Distributing \\$2 Billion More in Provider Relief Fund Payments to Health Care Providers Impacted by the COVID-19 Pandemic](#)

January 25, 2022 | *News Release*

FDA

Press Announcements

[Vaccines and Related Biological Products Advisory Committee March 3, 2022 Meeting Announcement - 03/03/2022](#)

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

Calendar

[Vaccines and Related Biological Products Advisory Committee March 3, 2022 Meeting Announcement - 03/03/2022](#)

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

January 26, 2022 *Press Briefings*

U.S. Department of State

<https://www.state.gov/coronavirus/releases/>

Media Notes

No new digest content identified.

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

[News: Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 24-27 January 2022 \(new\)](#)

CHMP, Last updated: 28/01/2022

[News: COVID-19: EMA recommends conditional marketing authorisation for Paxlovid \(updated\)](#)

CHMP, PRAC, Last updated: 28/01/2022

EMA's human medicines committee (CHMP) has recommended granting a conditional marketing authorisation for the oral antiviral medicine Paxlovid (PF-07321332 / ritonavir) for the treatment of COVID-19. The applicant is Pfizer Europe MA EEIG...

[News: Regulatory harmonisation of clinical trials in the EU: Clinical Trials Regulation to enter into application and new Clinical Trials Information System to be launched \(new\)](#)

Last updated: 25/01/2022

[News: Increase in manufacturing capacity for Vaxzevria \(previously COVID-19 Vaccine AstraZeneca\) \(new\)](#)

CHMP, Last updated: 24/01/2022

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

Publication

[Guidance on ending the isolation period for people with COVID-19, third update](#)

Technical report - 28 Jan 2022

Publication

[Communicable disease threats report, 23-29 January 2022, week 4](#)

Publication - 28 Jan 2022

News

[Societal pressure from unprecedented Omicron spread can be eased through increased vaccination uptake](#)

Press release - 27 Jan 2022

Publication

[Assessment of the further spread and potential impact of the SARS-CoV-2 Omicron variant of concern in the EU/EEA, 19th update](#)

Risk assessment - 27 Jan 2022

News

[Strengthening COVID-19 information and vaccination caravans in rural communities from Romania](#)

News - 27 Jan 2022

.....



European Centre for Disease Prevention and Control

COVID-19 Vaccine Tracker

Cumulative uptake of at least one dose in the total population in EU/EEA	Cumulative uptake of full vaccination in the total population in EU/EEA
73.9%	69.7%

Cumulative vaccine uptake (%) in the total population in EU/EEA countries as of 2022-01-21

by reporting week (data for the current week are preliminary)

Accessed 29 Jan 2022

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Statement 28 January 2022

European Health Union: new rules to improve clinical trials in the EU

As of Monday 31 January, the assessment and supervision of clinical trials throughout the EU will be harmonised, notably via a Clinical Trials Information System (CTIS) run by the European Medicines Agency.

[See Milestones above for detail]

Press release 25 January 2022

European Health Union: a stronger role for the European Medicines Agency

Today, as part of the on-going work to build a strong European Health Union, the Council has adopted the Regulation revising the mandate of the European Medicines Agency (EMA).

[See Milestones above for detail]

.....

.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

Vaccines received from COVAX	Vaccines received bilaterally	Vaccines received from AVATT
51	51	38
Countries	Countries	Countries




Africa CDC Vaccine Dashboard

Africa Vaccinated

Vaccine Administered (Total)	(63.61% of supply)
Partially Vaccinated	(16.10% of population)
Vaccination Completed	(10.99% of population)
Booster Dose	(0.59% of population)

Total of Supply Administered



Accessed 29 Jan 2022. Full scale, interactive dashboard available at:
<https://africacdc.org/covid-19-vaccination/>

.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

No new digest content identified.

.....
.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
29 January 2022, 08:00
IST (GMT+5:30)

(↑↓ Status change since
yesterday)

Active (4.91%)

2004333 (101278↓)

Discharged (93.89%)

38360710 (335939↑)

Deaths (1.21%)

493198 (871↑)

COVID-19 Vaccination
as on : 29 January
2022, 08:00 IST
(GMT+5:30)

Total Vaccination : 1,65,04,87,260 (56,72,766↑)

Government of India – Press Information Bureau

Latest Press Releases

COVID - 19 Vaccination Update - Day 379

:: India's cumulative vaccination coverage crosses 165.60 crore

:: More than 53 lakh Vaccine doses administered today till 7 pm

Posted On: 29 JAN 2022 8:11PM by PIB Delhi

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Jan 29: Daily briefing on novel coronavirus cases in China

On Jan 28, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 59 new cases of confirmed infections.

China beefs up COVID-19 alert at community level during Chinese New Year holiday

2022-01-29

Beijing upgrades measures to stem latest COVID-19 resurgence

2022-01-28

... Li Ang, deputy director of the Beijing Municipal Health Commission, said that Beijing had classified one new area in the district as medium-risk for COVID-19, which brought the number of medium-risk areas in the city to seven. Beijing also has one high-risk area.

On the basis of existing prevention and control measures in affected areas of Fengtai, the district government has rolled out a series of new measures including restrictions on leaving affected areas, daily nucleic acid testing, and encouraging telecommuting.

.....
.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 26 January 2022

:: ...“The polio programme has given me so much confidence. After I started working in polio, I had the confidence of meeting new people. Meeting family, going to weddings, all of it became easier. Before that, I had no confidence to even step out of the house,”- Soni Fahren, a polio worker nominated for the Presidential honour in Pakistan. [Read more...](#)

:: When the first consignment of COVID-19 vaccines arrived in Rumbek, the capital of Lakes State in South Sudan, WHO State Polio Officer Dr Jiel Jiel was prepared. In support of the Ministry of Health, and in collaboration with partners, he had been working for weeks to help coordinate the vaccine rollout, using skills gained from working to eradicate polio. [Read more...](#)

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- **DR Congo:** two cVDPV2 cases
- **Nigeria:** five cVDPV2 cases and 23 positive environmental samples
- **Ukraine:** one cVDPV2 case

.....
.....

Disease Outbreak News (DONs)

:: [Cholera – Benin 25 January 2022](#)

.....
.....

WHO/OCHA Emergencies

Health emergencies list - WHO

“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”

[Afghanistan crisis](#) *[Last apparent update: 17 Jan 2022]*

[Crisis in Northern Ethiopia](#) *[Last apparent update: 1 June 2021]*

[Ebola outbreak, Democratic Republic of the Congo, 2021](#) *[Last apparent update: 17 Aug 2021]*

[Ebola outbreak outbreak, N'Zerekore, Guinea, 2021](#) *[Last apparent update: 17 Aug 2021]*

[Coronavirus disease \(COVID-19\) pandemic](#) *[See COVID above]*

[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)

[Last apparent update: 17 Aug 2021]

[**Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020**](#)

[Last apparent update: 17 Aug 2021]

[**Ebola outbreak, Democratic Republic of the Congo, 2018**](#) *[Last apparent update: 24 July 2018]*

[**Yemen crisis**](#) *[Last apparent update: 12 February 2021]*

[**Syria crisis**](#) *[Last apparent update: 18 June 2021]*

[**Somalia crisis**](#) *[Last apparent update: 24 March 2018]*

[**Nigeria crisis**](#) *[Last apparent update: 1 Oct 2021]*

[**Ebola outbreak, Democratic Republic of the Congo, 2017**](#) *[Last apparent update: 17 Aug 2021]*

[**Zika virus disease outbreak, 2015-2016**](#) *[Last apparent update: 24 Jan 2020]*

[**Ebola outbreak: West Africa, 2014-2016**](#) *[Last apparent update: 17 Aug 2021]*

[**Iraq crisis**](#) *[Last apparent update: 9 Jan 2008]*

[**South Sudan crisis**](#) *[Last apparent update: 23 Sep 2020]*

[**Avian influenza A \(H7N9\) virus outbreak**](#) *[Last apparent update: 13 September 2021]*

[**Middle East respiratory syndrome \(MERS-CoV\) outbreak**](#) *[Last apparent update: 8 July 2019]*

[**Influenza A \(H1N1\) virus, 2009-2010 pandemic**](#) *[Last apparent update: 10 Aug 2010]*

.....

[**UN OCHA – Current Emergencies**](#)

Current Corporate Emergencies

Afghanistan

No new updates identified.

Northern Ethiopia

[**Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 27 January 2022**](#)

HIGHLIGHTS

- Humanitarian partners in Tigray continue to downsize operations due to the depletion of supplies, fuel, and cash, voicing concerns over ceasing operations by end of February.
- Zero therapeutic nutrition supplies in Tigray, including for the treatment of children with severe acute malnutrition.
- A shipment of medical supplies was transported via UNHAS flight to Mekelle on 24 January.
- More than 523,000 people reached with food assistance during the week under two food distribution rounds in Amhara.

- More than 60 unaccompanied and separated children, including 27 girls, were identified during the reporting period in Afar.

.....

WHO & Regional Offices [to 29 Jan 2022]

<https://www.who.int/>

News [Selected]

28 January 2022

Departmental news

WHO and Viamo provide critical access to COVID-19 information to the next billion digital users via their mobile phones

WHO is working with [Viamo](#), a global social enterprise improving lives via mobile, to provide WHO's COVID-19 information, including vaccines, to the hardest to reach populations, in their languages, through the mobile phones they own. This includes people with simple phones (feature phones) or with limited access to the internet...

Since the onset of COVID-19, Viamo's [3-2-1 Service](#) has become a trusted, toll-free source of life-saving COVID-19 health information for people in 19 countries. Listeners dial in and access important messages that help them make better informed decisions to live healthier lives.

To date, the WHO COVID-19 information has reached 1,292,209 people through Viamo's 3-2-1 Platform in 38 languages and across 13 countries on topics such as how COVID-19 spreads, how COVID-19 vaccines work, how they are developed and tested, COVID-19 safety, how long protection from COVID-19 vaccines and antibodies last, coping with COVID-19 (e.g., mental health and COVID-19, tips to promote well-being) and more....

28 January 2022

Departmental news

Use of alternative interferon-gamma release assays for the diagnosis of TB infection - WHO Policy Statement

27 January 2022

Departmental news

Ensuring quality and ethics of research on FGM: new WHO guidance out now

26 January 2022

Departmental news

Marking 2 years of pandemic learning response on OpenWHO.org

26 January 2022

Departmental news

Celebrating World NTD Day: make every day a neglected tropical diseases day

26 January 2022

Departmental news

New insights into quality of care for girls and women facing the complications of unsafe abortion

25 January 2022
Departmental news

[WHO webinar on Human Health Risk Assessment – Updated WHO Toolkit](#)

25 January 2022
Departmental news

[WHO establishes a Technical Advisory Group on Measurement, Monitoring and Evaluation of UN Decade of Healthy Ageing](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

No new digest content identified

WHO Region of the Americas PAHO

:: 28 Jan 2022 Neglected tropical diseases: PAHO calls for an end to delays in treatment in the Americas

These preventable and treatable conditions are almost absent from the global health agenda, with little attention and funding. Washington, DC, January 27, 2022 (PAHO)- On the eve of the first World Day for Neglected Tropical Diseases, the Pan American Health Organization (PAHO) is urging governments to provide comprehensive and universal care for...

:: 26 Jan 2022 Ongoing COVID-19 pandemic in the Americas threatens growth and development of children, says PAHO Director

Millions miss out on routine care, including vaccination. Educational crisis also impacts their social, mental, and physical wellbeing. Washington D.C. January 26 (PAHO) – As the COVID-19 outbreak reaches its third year in the Americas, millions of children are missing out on routine vaccinations, putting countries at risk of losing two decades...

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

:: Living with COVID-19 – 2 years on 27-01-2022

:: Twenty years of the Transport, Health and Environment Pan-European Programme 26-01-2022

:: Celebrating the CSO Initiative: building community readiness, response and resilience to emergencies 26-01-2022

:: WHO/ECDC report: antimicrobial resistance remains threat to health in European Region 26-01-2022

WHO Eastern Mediterranean Region EMRO

:: Severe snowstorm in northwest Syria creates challenges for health response 28 January 2022

:: Pakistan commended for commitment to eradicating polio 27 January 2022

WHO Western Pacific Region

No new digest content identified

.....

WHO Events

<https://www.who.int/news-room/events/2>

[Selected]

[Update on SARS-CoV-2 variant of concern Omicron](#)

1 February 2022 13:30 – 14:30 CET

[WHO Public Health Laboratories knowledge sharing webinars - SARS-CoV-2 variants, Emergency Use Listing \(EUL\) and diagnostics performance monitoring](#)

2 February 2022 11:00 – 12:30 CET

[Webinar: An investment case to end female genital mutilation](#)

3 February 2022 14:00 – 15:30 UTC Time

[The International Day of Zero Tolerance for Female Genital Mutilation \(FGM\)](#)

6 February 2022

[Webinar: Antimicrobial consumption - data for action](#)

7 February 2022

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected Titles

28 January 2022

[Use of alternative interferon-gamma release assays for the diagnosis of TB infection: WHO policy statement](#)

28 January 2022

[Report of the 21st meeting: Strategic and Technical Advisory Group for Tuberculosis \(STAG-TB\)](#)

28 January 2022

[Weekly epidemiological record, 2022, vol. 97, 04](#)

28 January 2022

[WHO Drug Information - Volume 35, No. 4](#)

27 January 2022

[The Selection and Use of Essential Medicines \(2021\) - TRS 1035](#)

Overview

The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and formulations on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists,

and update to the AWARe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.

27 January 2022

[The use of rectal artesunate as a pre-referral treatment for severe *P. falciparum* malaria](#)

26 January 2022

[Ethical considerations in research on female genital mutilation](#)

25 January 2022

[Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines...](#)

.....
.....
.....

CDC/ACIP [U.S.] [to 29 Jan 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements [Selected]

[CDC Statement on MMWR: COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021](#)

Thursday, January 20, 2022

.....

[ACIP Meetings](#)

Next meeting scheduled for February 23-24, 2022

[Draft Agenda – February 23-24, 2022](#)

.....

[MMWR News Synopsis Friday, January 28, 2022](#)

Selected Content

- [Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022](#)
- [Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021](#)
- [Previously Released: COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021](#)
- [Previously Released: COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021](#)
- [Previously Released: Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During](#)

Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

- Previously Released: Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022

.....

Coronavirus Disease 2019 (COVID-19)- CDC

Approximately 25 announcements/reports/data summaries.

- 1/28/22 Cases in the U.S.
- 1/28/22 Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 28 Jan 2022 06:00:00 EST
- 1/28/22 COVID-19 Guidance for Operating Early Care and Education/Child Care Programs
- 1/28/22 Staffing Resources
- 1/28/22 COVID-19 Vaccines While Pregnant or Breastfeeding
- 1/28/22 Interim Guidance for Case Investigation and Contact Tracing in K-12 Schools
- 1/28/22 COVID Data Tracker Weekly Review
- 1/28/22 Schools and Childcare Programs
- 1/27/22 Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021

.....

.....

Africa CDC [to 29 Jan 2022]

<http://www.africacdc.org/>

News

Capacity building for South Sudan health emergency responders on the Incident Management System

26 January 2022

Press Releases

Parsyl partners with Africa CDC to distribute 10,000 vaccine monitoring devices in support of continent's COVID-19 response

Addis Ababa, Ethiopia – January 24, 2022 — Parsyl, the leading provider of smart vaccine monitoring solutions in emerging markets, has announced that it will partner with the Africa Centres for Disease Control and Prevention (Africa CDC) to make available 10,000 vaccine monitoring devices to African Union member states in support of Covid-19 vaccine distribution on the continent.

Several different Covid-19 vaccines are being distributed in the developing world, each with unique stability and storage requirements. This creates complexity for frontline personnel responsible for managing the quality of these vaccines at point of use. Parsyl has simplified Covid-19 vaccine monitoring with affordable and user-friendly technology. The monitoring devices can be configured for the unique temperature requirements of multiple health products with a single, end-to-end solution...

.....

.....

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 29 Jan 2022]

<http://en.nhc.gov.cn/>

News

Jan 29: Daily briefing on novel coronavirus cases in China

On Jan 28, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 59 new cases of confirmed infections.

China beefs up COVID-19 alert at community level during Chinese New Year holiday

2022-01-29

Beijing upgrades measures to stem latest COVID-19 resurgence

2022-01-28

... Li Ang, deputy director of the Beijing Municipal Health Commission, said that Beijing had classified one new area in the district as medium-risk for COVID-19, which brought the number of medium-risk areas in the city to seven. Beijing also has one high-risk area.

On the basis of existing prevention and control measures in affected areas of Fengtai, the district government has rolled out a series of new measures including restrictions on leaving affected areas, daily nucleic acid testing, and encouraging telecommuting.

National Medical Products Administration – PRC [to 29 Jan 2022]

<http://english.nmpa.gov.cn/>

News

Nearly 2.99b COVID-19 vaccine doses administered on Chinese mainland

2022-01-29

Nearly 2.99 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Thursday, data from the National Health Commission showed on Jan 28.

CCDC Weekly Reports: Current Volume (4)

2022-01-28 / No. 4 COVID-19 ISSUE (22)

[View PDF of this issue](#)

- Preplanned Studies: Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
- Preplanned Studies: Willingness of the General Public to Receive A COVID-19 Vaccine Booster — China, April–May 2021
- Perspectives: Bubble Strategy — A Practical Solution to Return to Regular Life in the Intertwined Era of Vaccine Rollouts and Virus Mutation
- Perspectives: The Dynamic COVID-Zero Strategy in China
- Notes from the Field: The First Two Imported Cases of SARS-CoV-2 Omicron Variant — Tianjin Municipality, China, December 13, 2021

.....
.....

.....

Contents [click to move among sections]

Milestones - Perspectives

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

.....

.....

.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity [to 29 Jan 2022]

<https://www.airfinity.com/insights>

INSIGHTS & COMPANY NEWS

No new digest content identified.

Paul G. Allen Frontiers Group [to 29 Jan 2022]

<https://alleninstitute.org/news-press/>

News

[2021 Annual Report: unknown | known](#)

Good science often raises just as many questions as it answers.

January 24, 2022

Whether it's classifying the billions of neurons that make up our brain, tracing the lineages of our development or understanding the detailed ins and outs of our cells, Allen Institute scientists are making the unknown known — and ultimately helping us to understand what it means to be human.

BARDA – U.S. Department of HHS [to 29 Jan 2022]

<https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx>

News

[UPDATE -- Allocation of Bamlanivimab/Etesevimab and REGEN-COV Therapeutics Paused](#)

Monday, January 24, 2022

BMGF - Gates Foundation [to 29 Jan 2022]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

Bill & Melinda Gates Foundation Appoints Board of Trustees – Four New Members Join Co-Chairs Bill Gates and Melinda French Gates to Shape Foundation Governance and Increase Impact

In inaugural foundation annual letter, CEO Mark Suzman reflects on evolution of foundation's governance and work to fight poverty, disease, and inequity globally

SEATTLE (January 26, 2022) — Today, the Bill & Melinda Gates Foundation appointed a board of trustees, with Strive Masiyiwa, Baroness Nemat (Minouche) Shafik, Thomas J. Tierney, and Gates Foundation CEO Mark Suzman joining co-chairs Bill Gates and Melinda French Gates as members. The board members will work alongside Gates and French Gates, bringing independent and diverse perspectives to help strengthen the foundation's governance...

Bill & Melinda Gates Medical Research Institute [to 29 Jan 2022]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 29 Jan 2022]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 29 Jan 2022]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: **[Informed Consent: A Monthly Review – January 2022](#)** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 29 Jan 2022]

<http://cepi.net/>

Latest News

CEPI partners with BioNet to expand variant-proof vaccine programme

OSLO, Norway, 25 January 2022: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the latest award under its \$200m programme, launched in March 2021, to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other Betacoronaviruses.¹ CEPI will partner with BioNet—a French-Thai vaccine manufacturer and member of the Developing Country Vaccine Manufacturing network (DCVMN)—providing up to \$16.9 million to support preclinical studies, Phase I and Phase II clinical trials, production of necessary clinical trial material, and process and analytical development...

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 29 Jan 2022]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 29 Jan 2022]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 29 Jan 2022]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 29 Jan 2022]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 29 Jan 2022]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Fondation Merieux [to 29 Jan 2022]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 29 Jan 2022]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GHIT Fund [to 29 Jan 2022]

<https://www.ghitfund.org/newsroom/press>

No new digest content identified.

Global Fund [to 29 Jan 2022]

<https://www.theglobalfund.org/en/news/>

News & Stories

Global Fund Announces Shunsuke Mabuchi as New Head of Resilient and Sustainable Systems for Health

26 January 2022

Geneva – The Global Fund is pleased to announce that Shunsuke Mabuchi is joining the Global Fund as the new Head of Resilient and Sustainable Systems for Health, starting in March 2022. A senior global health leader, Shun brings a unique combination of experience and leadership in health systems strengthening, pandemic preparedness, program delivery and emergency response. He joins the Global Fund at a critical time for the implementation of the new strategy, and will focus on maximizing people-centered, integrated systems for health to deliver impact, resilience and sustainability...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 29 Jan 2022]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 29 Jan 2022]

<http://www.hillemanlabs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 29 Jan 2022]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Vaccines Project [to 29 Jan 2022]

<http://www.humanvaccinesproject.org/>

News

Press Release

Jan 25, 2022

2021 Michelson Prizes Push New Frontiers in Human Immunology

IAVI [to 29 Jan 2022]

<https://www.iavi.org/>

Latest News

Website not responding at inquiry.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 29 Jan 2022]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

Hacking the data of the world's most vulnerable is an outrage

ICRC's Director-General Robert Mardini addresses the recent cyber-attack on humanitarian data which puts humanitarian protection and assistance at risk.

29-01-2022 | Article

Explosive weapons: Civilians in populated areas must be protected

Explosive Weapons with Wide Area Effects: A Deadly Choice in Populated Areas - Report provides recommendations to protect civilians

26-01-2022 | Report

Wars in cities: protection of civilians in urban settings

I commend Norway and the leadership of Prime Minister Støre, for bringing attention to this critical humanitarian concern.

25-01-2022 | Statement

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 29 Jan 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

27/01/2022

Syria: Extremely harsh winter raises acute humanitar...

25/01/2022

Tonga: Aid ramped up after eruption and tsunami

25/01/2022

Philippines: New data reveals Typhoon Rai wrecked 1...

Institut Pasteur [to 29 Jan 2022]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

IOM / International Organization for Migration [to 29 Jan 2022]

<http://www.iom.int/press-room/press-releases>

News - Selected

News

28 Jan 2022

[Statement by the Director General António Vitorino on the Death of Demetrios G. Papademetriou](#)

News

28 Jan 2022

[IOM and UNOCT Sign Agreement to Collaborate on API/PNR Technical Assistance](#)

News

25 Jan 2022

[Intensifying Drought Threatens to Displace Over 1 Million People in Somalia](#)

ISC / International Science Council [to 29 Jan 2022]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News Blogs Podcasts

[Launch of a new ISC regional presence in Latin America and the Caribbean](#)

Ensuring regional resonance and global impact

28.01.2022

Following an [open call for expressions of interest](#) to host an International Science Council (ISC) regional presence in Latin America and the Caribbean, the ISC is delighted to announce that the Colombian Academy of Exact, Physical and Natural Sciences will host a Regional Focal Point for Latin America and the Caribbean (RFP-LAC), during the 2022 – 2024 term.

IVAC [to 29 Jan 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

[Webinar: Making COVID-19 vaccines APPEALing: Pilot message testing in India](#)

Registration: <https://bit.ly/3fYNdv0>

When: February 17, 2022 from 12:00pm-1:00pm ET

IVI [to 29 Jan 2022]

<http://www.ivl.int/>

IVI News & Announcements

New studies: Vi-DT vaccine is safe and immunogenic, with booster dosing potentially eliciting long-term immune responses

January 27, 2022 – SEOUL, Republic of Korea – A new study shows that late booster dosing with Vi polysaccharide conjugated with diphtheria toxoid (Vi-DT), one of the typhoid conjugate vaccines (TCVs), at 27.5 months post-first dose is safe and elicits robust immune responses in children aged 6-23 months. The findings from this study newly published online in [npj Vaccines](#) support the use of TCV booster doses to confer long-term protection against typhoid fever in young children...

IVI and NVI partner for collaborative vaccine R&D and capacity building

January 20, 2022

Johns Hopkins Center for Health Security [to 29 Jan 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

No new digest content identified.

MSF/Médecins Sans Frontières [to 29 Jan 2022]

<http://www.msf.org/>

Latest [Selected Announcements]

No new digest content identified.

National Academy of Medicine - USA [to 29 Jan 2022]

<https://nam.edu/programs/>

Selected News/Programs/Events

No new digest content identified.

National Academy of Sciences - USA [to 29 Jan 2022]

<http://www.nasonline.org/news-and-multimedia/>

News

National Academies Partner with Chan Zuckerberg Initiative on New Grant Program to Recognize and Further Leadership by Biomedical Researchers Who Promote Diversity Equity and Inclusion

January 25, 2022

The National Academies are partnering with the Chan Zuckerberg Initiative to administer a new funding opportunity that aims to recognize and further the leadership and scientific accomplishments of excellent biomedical researchers who - through outreach mentoring and teaching - have a record of promoting diversity equity and inclusion in their fields.

Safe Passage for Scientists - Evacuating Scientists and Engineers from Afghanistan

January 25, 2022

When the Taliban captured Kabul last year a group of scientists and engineers with ties to the National Academies were desperately seeking a way out of Afghanistan. During a recent webinar Vaughan Turekian recounted the effort to get these scientists and their families to safety.

National Vaccine Program Office - U.S. HHS [to 29 Jan 2022]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

National Vaccine Advisory Committee [NVAC] 2022 Meetings

[February 10-11, 2022](#)

NIH [to 29 Jan 2022]

<http://www.nih.gov/news-events/news-releases>

News Releases

[Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19](#)

January 27, 2022 — NIH trial compared hIVIG plus remdesivir to remdesivir alone.

[Mix-and-match trial finds additional dose of COVID-19 vaccine safe, immunogenic](#)

January 26, 2022 — NIH-sponsored study assessed dose in adults fully vaccinated with any EUA or approved COVID-19 vaccine

[Social connectedness, sleep, and physical activity associated with better mental health among youth during the COVID-19 pandemic](#)

January 24, 2022 — NIH-supported study also found girls were at higher risk for stress, anxiety, and depression than boys.

OECD [to 29 Jan 2022]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

Newsroom

No new digest content identified.

PATH [to 29 Jan 2022]

<https://www.path.org/media-center/>

Press Releases

No new digest content identified.

Sabin Vaccine Institute [to 29 Jan 2022]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 29 Jan 2022]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

28 January 2022

New report highlights vital role of community-led organizations in pandemic response and preparedness

In a new UNAIDS report, *Holding the line: communities as first responders to COVID-19 and emerging health threats*, organizations led by and for people living with HIV and key populations detail their efforts to respond to the colliding pandemics of COVID-19 and HIV. Drawing on qualitative survey data spanning 225 community-led organizations across 72 countries, the report provides a snapshot of the organizations' work during early 2020 to sustain the HIV response while supporting their communities through the COVID-19 pandemic. The report also illuminates the high-priority actions that are still urgently needed to ensure the continuity of HIV-related services, as well as the sustainability of the community-led organizations providing them...

UNHCR Office of the United Nations High Commissioner for Refugees [to 29 Jan 2022]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

Jordan issues record number of work permits to Syrian refugees

Country is at forefront of global efforts to give both refugees and host communities access to decent work

25 January 2022

UNICEF [to 29 Jan 2022]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Statement

01/27/2022

No excuses. Keep schools open. Children can't wait

Statement by UNICEF Executive Director Henrietta Fore

Press release

01/26/2022

Learning loss must be recovered to avoid long-term damage to children's wellbeing and productivity, new report says

New recommendations from the Global Education Evidence Advisory Panel (GEEAP) offer guidance on how to recover learning and prevent further loss, including prioritizing the full reopening of schools

Press release

01/23/2022

COVID:19 Scale of education loss 'nearly insurmountable', warns UNICEF

Media factsheet

Unitaid [to 29 Jan 2022]

<https://unitaid.org/>

Featured News

No new digest content identified.

USAID [to 29 Jan 2022]

<https://www.usaid.gov/news-information/press-releases/2021>

Selected Press Releases, Statements, Announcements

News

New USAID Initiatives in Honduras

January 27, 2022

As part of USAID's \$48 million commitment to help Honduras fight COVID-19, **USAID is providing an additional \$500,000 under the American Rescue Plan Act to promote delivery of and widespread and equitable access to safe and effective COVID-19 vaccinations.** Specifically, USAID will promote transparency and accountability in government COVID-19 efforts, strengthen vaccine information systems, increase data availability and use, and address issues of vaccine hesitancy and misinformation in vulnerable communities. These funds will help turn vaccines into vaccinations, including the 3.9 million doses already donated by the U.S. and several hundred thousand additional doses arriving in the next two months. USAID is also providing more than 500,000 pediatric syringes to enable the start of vaccinations for Honduran children.

Vaccine Equity Cooperative [nee Initiative] [to 29 Jan 2022]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative (Sabin) [to 29 Jan 2022]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 29 Jan 2022]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 29 Jan 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update Newsletter January 2022

Wellcome Trust [to 29 Jan 2022]

<https://wellcome.ac.uk/news>

News, Opinion, Reports

Explainer

Seven vital questions about RNA Covid-19 vaccines

27 January 2022

Opinion

Wellcome's ambitions for 2022 and beyond

24 January 2022

Cheryl Moore, Director of Research Programmes, shares how Wellcome plans to spend £16 billion over the next ten years to advance scientific discovery and take on the world's most pressing health issues.

The Wistar Institute [to 29 Jan 2022]

<https://www.wistar.org/news/press-releases>

Press Releases

Jan. 27, 2022

The Wistar Institute Hosts U.S. Department of Commerce Official Making Major Grant Announcements to Strengthen Workforce Pipelines in Philadelphia & Across the Nation

Wistar is a finalist of the STEM Talent Challenge to create a new life science workforce training program to address Pennsylvania industry growth and demand for skilled workers.

WFPHA: World Federation of Public Health Associations [to 29 Jan 2022]

<https://www.wfpha.org/>

Latest News - Blog

No new digest content identified.

World Bank [to 29 Jan 2022]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

Health and WASH Services Reaching Most Vulnerable Yemenis Despite Difficult Context

Synopsis Just over four years ago, as Yemenis struggled with the effects of armed conflict on their lives, the World Bank, UNICEF, and World Health Organization (WHO) joined forces with Yemen's Ministry...

Date: January 27, 2022 Type: Brief

Prioritizing Learning During COVID-19: The Most Effective Ways to Keep Children Learning During and Post-Pandemic

Recommendations of the Global Education Evidence Advisory Panel The short- and long-term impact of the Covid-19 crisis on children's education, wellbeing, and future productivity is profound. Almost two...

Date: January 26, 2022 Type: Publication

Learning Loss Must be Recovered to Avoid Long-term Damage to Children's Wellbeing and Productivity, New Report Says

New recommendations from the Global Education Evidence Advisory Panel (GEEAP) offer guidance on how to recover learning and prevent further loss, including prioritizing the full reopening of schools FLORENCE/LONDON/NEW...

Date: January 26, 2022 Type: Press Release

World Bank-financed Moderna vaccines arrive in Nepal to protect children and youth from COVID-19

KATHMANDU, January 25, 2022 – 1.66 million of the four million doses of Moderna vaccines financed by the World Bank arrived in Nepal yesterday. The remaining doses will be delivered shortly. Nepal will deploy these vaccines for adolescents 12-17 years to safeguard them from the health impacts of COVID-19.

The vaccines, procured under the COVAX cost-share option, comply with World Bank's Vaccine Approval Criteria for financing and are certified as safe and effective for children as young as 12 years of age by the European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency.

"Nepal was the second country globally to finalize procurement of vaccines through the COVAX cost-share scheme. The supply of Moderna vaccines is timely for Nepal, as we expand our vaccine coverage to adolescents 12-17 years of age," said Mr. Birodh Khatiwada, Honorable Minister of Health and Population. "The Government is committed to vaccinating the entire eligible population by mid-April 2022 and the World Bank-financed Moderna vaccines will be instrumental in helping Nepal achieve its COVID-19 vaccination goal."

In line with the recommendations of the National Immunization Advisory Committee and the National Immunization Committee, the Moderna vaccines will be administered to adolescent populations through immunization sites set up in schools, as well as sites to reach out-of-school adolescent populations...

World Organisation for Animal Health (OIE) [to 29 Jan 2022]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 29 Jan 2022]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

Registrations open for WTO workshop on COVID-19 vaccines R&D, manufacturing and distribution

28 January 2022

With the objectives of supporting ongoing discussions and improving understanding of the practical aspects of COVID-19 vaccine research and development (R&D), manufacturing and distribution, the WTO Secretariat is organizing a technical workshop on 11 February 2022.

WTO Members discuss way forward in dedicated meeting on WTO pandemic response

27 January 2022

WTO members met on 27 January to discuss the WTO response to the COVID-19 pandemic. The informal meeting convened by the Chair of the General Council, Ambassador Dacio Castillo of Honduras, looked at issues related to cross-border trade flows and the proposal to waive certain intellectual property protections related to COVID-19 countermeasures. Director-General Ngozi Okonjo-Iweala called on members to move swiftly to try and reach a comprehensive outcome by the end of February.

[See Perspectives above for detail]

.....

ARM [Alliance for Regenerative Medicine] [to 29 Jan 2022]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 29 Jan 2022]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 29 Jan 2022]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 29 Jan 2022]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 29 Jan 2022]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

[IFPMA, BIO and DCVMN Statement on Influenza Preparedness for WHO EB150 agenda item 15.4](#)

28 January 2022

Industry welcomes the progress made so far in influenza preparedness, although we wish to call out 3 key policy areas where much work still needs to be done: 1) improving seasonal influenza vaccine coverage, 2) addressing the increasing challenges and barriers being posed by national ABS legislation in accessing pathogen samples, and 3) in finally defining how to declare an influenza pandemic – still an open item at WHO more than 10 years after the last pandemic. It is also essential to ensure that the expansion of GISRS to include SARS-CoV-2 and RSV does not undermine the excellent work being done so far for influenza surveillance.

We are concerned to see that generic antiviral manufacturers are signing voluntary SMTA-2s under the PIP Framework, when for IFPMA, BIO and DCVMN members those are mandatory for access to pandemic influenza virus samples. We ask WHO to clarify why those are not mandatory agreements as well, as this could create a major gap in access to antivirals in the event of a pandemic as the majority of global supply of antivirals is now with generic manufacturers.

Finally, we reiterate our concerns about national ABS legislation continuing to hinder access to physical samples of influenza viruses. This is no longer just 'a risk', it is a reality: in 2021 one manufacturer lost 40% of their vaccine production capacity due to the inability to use the best strain for manufacturing, as there was no legal clarity regarding the use of that strain from a certain country. Measures such as potentially expanding the PIP Framework, a non-legally binding instrument, would simply not address such issues, and could weaken the Framework by forcing its reopening for negotiation.

IFPMA and GSCF Statement on Non-Communicable Diseases for WHO EB150 agenda item 7

24 January 2022

IFPMA Statement on Pandemic Preparedness and Response for EB150 agenda item 15.1

24 January 2022

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 29 Jan 2022]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 29 Jan 2022]

<http://www.phrma.org/>

Latest News [Selected]

No new digest content identified.

* * * *

Contents [click to move among sections]

::

Milestones - Perspectives

:: *Coronavirus [COVID-19] - WHO*

:: *Emergencies*

:: *Organization Announcements*

:: *Journal Watch*

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 13, 2022 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

Article

Ethics Consultation in U.S. Hospitals: New Findings about Consultation Practices

Ellen Fox, Marion Danis, Anita J. Tarzian & Christopher C. Duke

Pages: 1-9

Published online: 17 Nov 2021

Article

Should Feedback of Individual Results be Integrated into the Consent Process in African Genomics? Participants' Views from an HIV-TB Genomics Research Project in Botswana

Dimpho Ralefala, Mary Kasule, Ambroise Wonkam, Mogomotsi Matshaba & Jantina de Vries

Pages: 48-56

Published online: 01 Jul 2021

AMA Journal of Ethics

Volume 24, Number 1: E1-105 Jan 2022

<https://journalofethics.ama-assn.org/issue/inequity-along-medicaldental-divide>

Inequity Along the Medical/Dental Divide

Dental and medical health systems in the United States have evolved as fully separate entities. This division exacerbates health inequity, since patients' poor oral health affects their general health. The professionally entrenched view that what's in patients' mouths is somehow isolated from what's going on in the rest of their bodies is one all clinicians need to resist, since this view can be a source of harm, particularly among vulnerable patients and communities. Practical and ethical strategies for better aligning medical and dental goals of care are considered in this issue.

American Journal of Infection Control

January 2022 Volume 50 Issue 1 p1-122

<http://www.ajicjournal.org/current>

Major Articles

[Reviewed earlier]

American Journal of Preventive Medicine

February 2022 Volume 62 Issue 2 p149-306

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

January 2022 112(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 6 (Dec 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/6/tpmd.105.issue-6.xml>

[Reviewed earlier]

Annals of Internal Medicine

January 2022 Volume 175, Issue 1

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 302 January 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/302/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 29 Jan 2022)

[No new digest content identified]

BMJ Global Health

January 2022 - Volume 7 - 1

<https://gh.bmj.com/content/7/1>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 29 Jan 2022)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 29 Jan 2022)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 29 Jan 2022)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 29 Jan 2022)

Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France

Vaccination is expected to change the epidemiology and management of SARS-CoV-2 epidemics.

Authors: Paolo Bosetti, Cécile Tran Kiem, Alessio Andronico, Vittoria Colizza, Yazdan Yazdanpanah, Arnaud Fontanet, Daniel Benamouzig and Simon Cauchemez

Citation: BMC Medicine 2022 20:33

Content type: Research article

Published on: 26 January 2022

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 29 Jan 2022)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 29 Jan 2022)

Disparities in HPV vaccine knowledge and adolescent HPV vaccine uptake by parental nativity among diverse multiethnic parents in New Jersey

Suboptimal human papillomavirus (HPV) vaccination rates persist among adolescents in the United States (U.S.). New Jersey (NJ), among the top, most racially/ethnically diverse states in the U.S., had among the...

Authors: Bianca Anuforo, Jennifer K. McGee-Avila, Lindsey Toler, Baichen Xu, Racquel E. Kohler, Sharon Manne and Jennifer Tsui

Citation: BMC Public Health 2022 22:195

Content type: Research article

Published on: 29 January 2022

Socioeconomic inequalities in non- coverage of full vaccination among children in Bangladesh: a comparative study of Demographic and Health Surveys, 2007 and 2017–18

Vaccination is considered as a powerful and cost-effective weapon against many communicable diseases. An increase in full vaccination among the most vulnerable populations in Bangladesh was observed in the la...

Authors: Shobhit Srivastava, T. Muhammad, Rashmi Rashmi and Pradeep Kumar

Replacing vaccine paper package inserts: a multi-country questionnaire study on the acceptability of an electronic replacement in different target groups

In the European Union it is mandatory to include paper package leaflets (PPL) with all medicines, including vaccines, to inform the recipient. However, it is difficult to meet the necessity for localized PPLs ...

Authors: Martina Bamberger, Hans De Loof, Charlotte Marstboom, Stéphanie Oury, Paolo Bonanni, Odile Launay, Mira Kojouharova and Pierre Van Damme

Citation: BMC Public Health 2022 22:156

Content type: Research article

Published on: 24 January 2022

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 29 Jan 2022)

[No new digest content identified]

BMJ Evidence-Based Medicine

February 2022 - Volume 27 - 1

<https://ebm.bmj.com/content/27/1>

[Reviewed earlier]

BMJ Open

January 2022 - Volume 12 - 1

<https://bmjopen.bmj.com/content/12/1>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 100(1); 2022 Jan 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/397045/>

[Reviewed earlier]

Cell

Jan 20, 2022 Volume 185 Issue 2 p221-400

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 48, Issue 1 Pages: 1-175 January 2022

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 111, Issue 1 Pages: 1-331 January 2022

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

December 2021 Volume 43 Issue 12 p2041-2172
<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 18 Issue 6, December 2021
<https://journals.sagepub.com/toc/ctja/18/6>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 29 Jan 2022]
[No new digest content identified]

Contemporary Clinical Trials

Volume 112 January 2022
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/112/suppl/C>
[No new digest content identified]

The CRISPR Journal

Volume 4, Issue 6 / December 2021
<https://www.liebertpub.com/toc/crispr/4/6>
[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 4, December 2021
<https://link.springer.com/journal/40142/volumes-and-issues/9-4>
[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2022 - Volume 35 - Issue 1
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>
[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020
<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>
[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 4 Pages: 149-238 December 2021
<https://onlinelibrary.wiley.com/toc/14718847/current>
[Reviewed earlier]

Development in Practice

Volume 31, Issue 8, 2021
<http://www.tandfonline.com/toc/cdip20/current>
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 5 - October 2021
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>
[Reviewed earlier]

Disasters

Volume 46, Issue 1 Pages: 1-298 January 2022
<https://onlinelibrary.wiley.com/toc/14677717/current>
[Reviewed earlier]

EMBO Reports

Volume 23 Issue 1 5 January 2022
<https://www.embopress.org/toc/14693178/current>
[Reviewed earlier]

Emerging Infectious Diseases

Volume 28, Number 1—January 2022
<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 37 December 2021
<https://www.sciencedirect.com/journal/epidemics/vol/37/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>
[Reviewed earlier]

Ethics & Human Research

Volume 44, Issue 1 Pages: 1-39 January–February 2022

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

Ethics & International Affairs

Fall 2021 (35.3) | October 2021

<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J. Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupać on ethical AI, gender equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 19 December 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/19/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 31, Issue 6, December 2021

<https://academic.oup.com/eurpub/issue/31/6>

[Reviewed earlier]

Expert Review of Vaccines

Vol 20 (12) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Forum for Development Studies

Volume 48, 2021 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 29 Jan 2022]

[No new digest content identified]

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 4 December 31, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 29 Jan 2022]

[No new digest content identified]

Global Public Health

Volume 17, Issue 1 (2022)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 29 Jan 2022]

[**The challenges of severe acute respiratory syndrome coronavirus 2 \(SARS-CoV-2\) testing in low-middle income countries and possible cost-effective measures in resource-limited settings**](#)

Authors: Zamathombeni Duma, Anil A. Chuturgoon, Veron Ramsuran, Vinodh Edward, Pragalathan Naidoo, Miranda N. Mpaka-Mbatha, Khethiwe N. Bhengu, Nomzamo Nembe, Roxanne Pillay, Ravesh Singh and Zilungile L. Mkhize-Kwitshana

Content type: Review

22 January 2022

Health and Human Rights

Volume 23, Issue 2, December 2021

<https://www.hhrjournal.org/volume-23-issue-2-december-2021/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 17 - Special Issue 1 - January 2022

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

SPECIAL ISSUE: Country Responses to the COVID-19 Pandemic

Articles analyzing country responses in Australia, New Zealand, Canada, U.S., Belgium, Netherlands, Sweden, France, Italy

Health Policy and Planning

Volume 37, Issue 1, January 2022

<https://academic.oup.com/heapol/issue/37/1>

[New issue; No digest content identified.]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 29 Jan 2022]

[No new digest content identified]

Human Gene Therapy

Volume 33, Issue 1-2 / January 2022

<https://www.liebertpub.com/toc/hum/33/1-2>

[Reviewed earlier]

Humanitarian Exchange Magazine

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

Localisation and local humanitarian action

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 11, 2021

<https://www.tandfonline.com/toc/khvi20/current>

Article

Expanded principles of ethics and its implementation during COVID-19 vaccine trials: A scoping evidence based research synthesis

Vaibhav Kumar, Venetia Aranha, Rajni Rajgarhia, Abhishek Royal & Kedar Mehta

Pages: 3843-3849

Published online: 15 Jul 2021

Article

R0 of COVID-19 and its impact on vaccination coverage: compared with previous outbreaks

Mohamed Elsaid, Mostafa Ayman Nasef & Nguyen Tien Huy

Pages: 3850-3854

Published online: 06 Oct 2021

Article

Tracking the progress in COVID-19 and vaccine safety research – a comprehensive bibliometric analysis of publications indexed in Scopus database

Tosin Yinka Akintunde, Shaojun Chen, Taha Hussein Musa, Felix Oluseyi Amoo, Adekunle Adedeji, Elhakim Ibrahim, Angwi Enow Tassang, Idriss Hussein Musa & Hassan Hussein Musa

Pages: 3887-3897

Published online: 06 Oct 2021

Article

Lessons learned from COVID-19 vaccination in Indonesia: experiences, challenges, and opportunities

Bondi Arifin & Titik Anas

Pages: 3898-3906

Published online: 06 Oct 2021

Article

Intention to get COVID-19 vaccines: Exploring the role of attitudes, subjective norms, perceived behavioral control, belief in COVID-19 misinformation, and vaccine confidence in Northern India

Fatema Husain, Md Ghazi Shahnawaz, Neda Haseeb Khan, Heena Parveen & Krishna Savani

Pages: 3941-3953

Published online: 21 Sep 2021

Article

Willingness and influential factors of parents of 3-6-year-old children to vaccinate their children with the COVID-19 vaccine in China

Xiao Wan, Haitao Huang, Jia Shang, Zhenxing Xie, Ruiying Jia, Guangli Lu & Chaoran Chen

Pages: 3969-3974

Published online: 03 Aug 2021

article commentary

COVID-19 vaccination passport: prospects, scientific feasibility, and ethical concerns

Khan Sharun, Ruchi Tiwari, Kuldeep Dhama, Ali A. Rabaan & Saad Alhumaid

Pages: 4108-4111

Published online: 22 Jul 2021

Article

Fake COVID-19 vaccines: scams hampering the vaccination drive in India and possibly other countries

Om Prakash Choudhary, Priyanka, Indraj Singh, Teroj A. Mohammed & Alfonso J. Rodriguez-Morales

Pages: 4117-4118

Published online: 06 Aug 2021

Article

Mapping the global research output on Ebola vaccine from research indexed in web of science and scopus: a comprehensive bibliometric analysis

Tosin Yinka Akintunde, Taha Hussein Musa, Hassan Hussein Musa, Shaojun Chen, Elhakim Ibrahim, Sayibu Muhideen & Joseph Kawuki

Pages: 4246-4258

Published online: 16 Jul 2021

review article

Understanding the determinants of vaccine hesitancy and vaccine confidence among adolescents: a systematic review

Chiara Cadeddu, Carolina Castagna, Martina Sapienza, Teresa Eleonora Lanza, Rosaria Messina, Manuela Chiavarini, Walter Ricciardi & Chiara de Waure

Pages: 4470-4486

Published online: 02 Sep 2021

Immunity

Jan 11, 2022 Volume 55 Issue 1 p1-184

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 29 Jan 2022]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 29 Jan 2022]

Feasibility, acceptability, and effectiveness of non-pharmaceutical interventions against infectious diseases among crisis-affected populations: a scoping review

Non-pharmaceutical interventions (NPIs) are a crucial suite of measures to prevent and control infectious disease outbreaks. Despite being particularly important for crisis-affected populations and those living...

Authors: Jonathan A. Polonsky, Sangeeta Bhatia, Keith Fraser, Arran Hamlet, Janetta Skarp, Isaac J. Stopard, Stéphane Hugonnet, Laurent Kaiser, Christian Lengeler, Karl Blanchet and Paul Spiegel

Citation: Infectious Diseases of Poverty 2022 11:14

Content type: Scoping Review
Published on: 28 January 2022

International Health

Volume 14, Issue 1, January 2022
<https://academic.oup.com/inthealth/issue/14/1>
[New issue; No digest content identified]

International Human Rights Law Review

Volume 10 (2021): Issue 2 (Dec 2021)
<https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml>
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 9, No 1 (2022) January 2022
<https://www.ijcmph.com/index.php/ijcmph/issue/view/84>
[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 6, December 2021
<https://academic.oup.com/ije/issue>
[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 5 2021
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5>
Table of Contents
[Reviewed earlier]

International Journal of Infectious Diseases

January 2022 Volume 114 p1-278
<https://www.ijidonline.com/current>
[Reviewed earlier]

JAMA

January 25, 2022, Vol 327, No. 4, Pages 305-401
<https://jamanetwork.com/journals/jama/currentissue>
Original Investigation
[**Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021**](#)
Matthew E. Oster, MD, MPH; David K. Shay, MD, MPH; John R. Su, MD, PhD, MPH; et al.

free access has active quiz

JAMA. 2022;327(4):331-340. doi:10.1001/jama.2021.24110

This descriptive study compares the effect of mRNA-based COVID-19 vaccination with BNT162b2 (Pfizer-BioNTech) vs mRNA-1273 (Moderna) on the reported cases of myocarditis in the US after each vaccination dose.

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel

Avishay Spitzer, MD; Yoel Angel, MD, MBA; Or Marudi, MSc; et al.

free access has active quiz

JAMA. 2022;327(4):341-349. doi:10.1001/jama.2021.23641

This cohort study estimates the association of a BNT162b2 (Pfizer-BioNTech) vaccine booster dose with SARS-CoV-2 infections among health care workers in Israel previously vaccinated with a 2-dose series of BNT162b2.

Viewpoint

Winter of Omicron—The Evolving COVID-19 Pandemic

Carlos del Rio, MD; Saad B. Omer, MBBS, MPH, PhD; Preeti N. Malani, MD, MSJ

free access has multimedia has audio

JAMA. 2022;327(4):319-320. doi:10.1001/jama.2021.24315

This Viewpoint discusses the Omicron variant of SARS-CoV-2, including its likely origin, the importance of vaccination, the other tools available to combat a surge in COVID-19 cases, and the possibility of a “twindemic” with influenza.

Editorial

Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection

Anna Wald, MD, MPH

JAMA Network

COVID-19 Update January 29, 2022

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

January 2022, Vol 176, No. 1, Pages 7-108

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBİ Evidence Synthesis

January 2022 - Volume 20 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

EDITORIAL

Managing unmanageable loads of evidence: are living reviews the answer?

Kelly, Shannon E.; Curran, Janet A.; Tricco, Andrea C.

JBİ Evidence Synthesis. 20(1):1-2, January 2022.

SYSTEMATIC REVIEW PROTOCOLS

Identifying COVID-19 and H1N1 vaccination hesitancy or refusal among health care providers across North America, the United Kingdom, Europe, and Australia: a scoping review protocol

Gallant, Allyson J.; Steenbeek, Audrey; Curran, Janet A.

JBİ Evidence Synthesis. 20(1):173-180, January 2022.

Parental experiences of caring for their preschool children after declining vaccines: a qualitative systematic review protocol

Huel, Christine; Harding, Jillian; MacKinnon, Karen; More

JBİ Evidence Synthesis. 20(1):196-203, January 2022.

Journal of Adolescent Health

January 2022 Volume 70 Issue 1 p1-170

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 73 (2022)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 46, issue 6, December 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-6>

[Reviewed earlier]

Journal of Development Economics

Volume 154 January 2022

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/154/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 17 Issue 1-2, February-April 2022

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

January 2022 - Volume 76 - 1

<https://jech.bmj.com/content/76/1>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 4 Pages: 257-345 December 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 17, Issue 2, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 4, November 2021

<https://muse.jhu.edu/issue/46802>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 23, issue 6, December 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-6>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 20, 2022 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[New issue; No digest content identified]

Journal of Infectious Diseases

Volume 225, Issue 1, 1 January 2022

<https://academic.oup.com/jid/issue/225/1>

MAJOR ARTICLES AND BRIEF REPORTS

Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

Yaki Saciuk, Jennifer Kertes, Naama Shamir Stein, Anat Ekka Zohar

The Journal of Infectious Diseases, Volume 225, Issue 1, 1 January 2022, Pages 30–33,

<https://doi.org/10.1093/infdis/jiab556>

Providing a third dose of BNT152b2 6 months after the first 2 doses evidenced a vaccine effectiveness against infection rate of 89%. The reduction in infection risk 2 months after the third-dose vaccination campaign reinforces the wisdom of its implementation.

Journal of Medical Ethics

January 2022 - Volume 48 - 1

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 9, Issue 1 (2022)

<https://institutionalrepository.aah.org/jpcrr/>

[New issue; No digest content identified]

Journal of Pediatrics

January 2022 Volume 240 p1-324

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 29 Jan 2022]

[No new digest content identified]

Journal of Public Health Management & Practice

January/February 2022 - Volume 28 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 4, December 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-4>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

January 2022 Volume 19 Issue 186

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 29, Issue 1, January 2022

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 96 Number 1 January 2022

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Jan 29, 2022 Volume 399 Number 10323 p411-494, e2

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

[Neglected tropical diseases: ending the neglect of populations](#)

The Lancet

Comment

[COVID-19 will continue but the end of the pandemic is near](#)

Christopher J L Murray

Articles

[Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study](#)

Nicole Wolter, et al.

Open Access

[Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial](#)

Lulu Bravo, et al.

Health Policy

[Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability](#)

[Suerie Moon, PhD](#) [Jana Armstrong, MBA](#) [Brian Hutler, PhD](#) [Prof Ross Upshur, MD](#) [Rachel Katz, MA](#) [Caesar Atuire, PhD](#) et al. [Show all authors](#)

Published: December 10, 2021

DOI: [https://doi.org/10.1016/S0140-6736\(21\)02344-8](https://doi.org/10.1016/S0140-6736(21)02344-8)

Summary

The Access to COVID-19 Tools Accelerator (ACT-A) is a multistakeholder initiative quickly constructed in the early months of the COVID-19 pandemic to respond to a catastrophic breakdown in global cooperation. ACT-A is now the largest international effort to achieve equitable access to COVID-19 health technologies, and its governance is a matter of broad public importance. We traced the evolution of ACT-A's governance through publicly available documents and analysed it against three principles embedded in the founding mission statement of ACT-A: participation, transparency, and accountability. We found three challenges to realising these principles. First, the roles of the various organisations in ACT-A decision making are unclear, obscuring who might be accountable to whom and for what. Second, the absence of a clearly defined decision making body; ACT-A instead has multiple centres of legally binding decision making and uneven arrangements for information transparency,

inhibiting meaningful participation. Third, the nearly indiscernible role of governments in ACT-A, raising key questions about political legitimacy and channels for public accountability. With global public health and billions in public funding at stake, short-term improvements to governance arrangements can and should now be made. Efforts to strengthen pandemic preparedness for the future require attention to ethical, legitimate arrangements for governance.

The Lancet Child & Adolescent Health

Jan 2022 Volume 6 Number 1 p1-70, e1-e4

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jan 2022 Volume 4 Number 1 e1-e74

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jan 2022 Volume 10 Number 1 e1-e153

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jan 2022 Volume 22 Number 1 p1-150, e1-e40

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jan 2022 Volume 7 Number 1 e1-e92

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Jan 2022 Volume 10 Number 1 p1-120, e1-e10

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 26, issue 1, January 2022

<https://link.springer.com/journal/10995/volumes-and-issues/26-1>

[New issue; No digest content identified]

Medical Decision Making (MDM)

Volume 42 Issue 1, January 2022

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 4 Pages: 853-1206 December 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 601 Issue 7894, 27 January 2022

<https://www.nature.com/nature/volumes/601/issues/7894>

Article | 23 November 2021 | Open Access

[A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity](#)

A phase I open-label trial evaluating the immunogenicity, reactogenicity and safety of a peptide-based SARS-CoV-2 vaccine candidate to induce SARS-CoV-2-specific T cell responses.

Jonas S. Heitmann, Tatjana Bilich, Juliane S. Walz

Nature Biotechnology

Volume 40 Issue 1, January 2022

<https://www.nature.com/nbt/volumes/40/issues/1>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 29 Jan 2022)

[No new digest content identified]

Nature Genetics

Volume 54 Issue 1, January 2022

<https://www.nature.com/ng/volumes/54/issues/1>

[Reviewed earlier]

Nature Human Behaviour

Volume 6 Issue 1, January 2022

<https://www.nature.com/nathumbehav/volumes/6/issues/1>

Review Article | 15 November 2021

[The past, present and future of Registered Reports](#)

Registered Reports were introduced a decade ago as a means for improving the rigour and credibility of confirmatory research. Chambers and Tzavella overview the format's past, its current status and future developments.

Christopher D. Chambers, Loukia Tzavella

Feature | 27 January 2022

The future of human behaviour research

Human behaviour is complex and multifaceted, and is studied by a broad range of disciplines across the social and natural sciences. To mark our 5th anniversary, we asked leading scientists in some of the key disciplines that we cover to share their vision of the future of research in their disciplines. Our contributors underscore how important it is to broaden the scope of their disciplines to increase ecological validity and diversity of representation, in order to address pressing societal challenges that range from new technologies, modes of interaction and sociopolitical upheaval to disease, poverty, hunger, inequality and climate change. Taken together, these contributions highlight how achieving progress in each discipline will require incorporating insights and methods from others, breaking down disciplinary silos.

Janet M. Box-Steffensmeier, Jean Burgess, Claudia Wagner

Nature Medicine

Volume 28 Issue 1, January 2022

<https://www.nature.com/nm/volumes/28/issues/1>

News Feature | 14 January 2022

Rise of the preprint: how rapid data sharing during COVID-19 has changed science forever

Medical discoveries have been shared at an unprecedented pace during the COVID-19 pandemic, but so have fraudulent studies, which has led to worries about scientific integrity.

Clare Watson

World View | 17 January 2022

COVID-19 has revealed a pandemic of inequality

Pervasive inequality in the Americas has fueled the COVID-19 pandemic and must be tackled.

Carissa F. Etienne

Review Article | 20 January 2022

AI in health and medicine

AI has the potential to reshape medicine and make healthcare more accurate, efficient and accessible; this Review discusses recent progress, opportunities and challenges toward achieving this goal.

Pranav Rajpurkar, Emma Chen, Eric J. Topol

Review Article | 21 January 2022

A guide to immunotherapy for COVID-19

This Review aims to support clinical decision-making by providing an overview of the evidence for immunotherapy strategies in patients with COVID-19.

Frank L. van de Veerdonk, Evangelos Giamarellos-Bourboulis, Mihai G. Netea

Nature Reviews Genetics

Volume 23 Issue 1, January 2022

<https://www.nature.com/nrg/volumes/23/issues/1>
[Reviewed earlier]

Nature Reviews Immunology

Volume 22 Issue 1, January 2022

<https://www.nature.com/nri/volumes/22/issues/1>
[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 21 Issue 1, January 2022

<https://www.nature.com/nrd/volumes/21/issues/1>
[Reviewed earlier]

New England Journal of Medicine

January 27, 2022 Vol. 386 No. 4

<https://www.nejm.org/toc/nejm/medical-journal>
Perspective

[**Universal Coronavirus Vaccines — An Urgent Need**](#) D.M. Morens, J.K. Taubenberger, and A.S. Fauci

Original Articles

[**Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients**](#) R.L. Gottlieb and Others

[Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines](#) N. Andrews and Others

Editorials

[**Audio Interview: Addressing the Omicron Variant of SARS-CoV-2**](#) E.J. Rubin, L.R. Baden, J.A. Barocas, and S. Morrissey

Pediatrics

Volume 149, Issue 1 January 2022

<https://pediatrics.aappublications.org/>
[Reviewed earlier]

PharmacoEconomics

Volume 40, issue 1, January 2022

<https://link.springer.com/journal/40273/volumes-and-issues/40-1>
[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>
(Accessed 29 Jan 2022)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 29 Jan 2022)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 29 Jan 2022)

[COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination](#)

Ivan Gentile, Nicola Schiano Moriello

Perspective | published 28 Jan 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003917>

[Pandemic health consequences: Grasping the long COVID tail](#)

Kieran L. Quinn, Chaim M. Bell

Perspective | published 25 Jan 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003891>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 29 Jan 2022)

[Perceived COVID-19 vaccine effectiveness, acceptance, and drivers of vaccination decision-making among the general adult population: A global survey of 20 countries](#)

Roy Rillera Marzo, Absar Ahmad, Md. Saiful Islam, Mohammad Yasir Essar, Petra Heidler, Isabel King, Arulmani Thiyagarajan, Kittisak Jermsittiparsert, Karnjana Songwathana, Delan Ameen Younus, Radwa Abdullah El-Abasiri, Burcu Kucuk Bicer, Nhat Tan Pham, Titik Respati, Susan Fitriyana, Erwin Martinez Faller, Aries Moralidad Baldonado, Md Arif Billah, Yadanar Aung, Shehu Muhammad Hassan, Muhammad Mujtaba Asad, Kareem Ahmed El-Fass, Sudip Bhattacharya, Sunil Shrestha, Nouran Ameen Elsayed Hamza, Pascal Friedmann, Michael Head, Yulan Lin, Siyan Yi

Research Article | published 28 Jan 2022 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0010103>

[Defining clinical trial quality from the perspective of resource-limited settings: A qualitative study based on interviews with investigators, sponsors, and monitors conducting clinical trials in sub-Saharan Africa](#)

Angela De Pretto-Lazarova, Claudia Fuchs, Peter van Eeuwijk, Christian Burri

Research Article | published 27 Jan 2022 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0010121>

PLoS One

<http://www.plosone.org/>

[Accessed 29 Jan 2022]

Research Article

Assessment of vaccination timeliness and associated factors among children in Toke Kutaye district, central Ethiopia: A Mixed study

Kuma Dirirsa, Mulugeta Makuria, Ermias Mulu, Berhanu Senbeta Deriba

Research Article | published 27 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0262320>

Epidemics and local governments in struggling nations: COVID-19 in Lebanon

Jida M. Al-Mulki, Mahmoud H. Hassoun, Salim M. Adib

Research Article | published 27 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0262048>

A darkening spring: How preexisting distrust shaped COVID-19 skepticism

J. Hunter Priniski, Keith J. Holyoak

Research Article | published 26 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263191>

Determinants of maternal influenza vaccination in the context of low- and middle-income countries: A systematic review

Shrish Raut, Aditi Apte, Manikandan Srinivasan, Nonita Dudeja, Girish Dayma, Bireshwar Sinha, Ashish Bavdekar

Research Article | published 26 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0262871>

COVID-19 vaccine hesitancy among medical and health science students attending Wolkite University in Ethiopia

Ayenew Mose, Kassahun Haile, Abebe Timerga

Research Article | published 25 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263081>

COVID-19 vaccination beliefs, attitudes, and behaviours among health and social care workers in the UK: A mixed-methods study

Sadie Bell, Richard M. Clarke, Sharif A. Ismail, Oyinkansola Ojo-Aromokudu, Habib Naqvi, Yvonne Coghill, Helen Donovan, Louise Letley, Pauline Paterson, Sandra Mounier-Jack

Research Article | published 24 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0260949>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 29 Jan 2022]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

January 04, 2022; vol. 119 no. 1

<https://www.pnas.org/content/119/1>

[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 36 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 154 January 2022

<https://www.sciencedirect.com/journal/preventive-medicine/vol/154/suppl/C>

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Proceedings of the Royal Society B

26 January 2022 Volume 289 Issue 1967

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 202 Pages 1-138 (January 2022)

<https://www.sciencedirect.com/journal/public-health/vol/202/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 14, Issue 3, November 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 136 Issue 6, November/December 2021

<https://journals.sagepub.com/toc/phrg/136/6>

[Reviewed earlier]

Qualitative Health Research

Volume 32 Issue 2, January 2022

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

Research Ethics

Volume 18 Issue 1, January 2022

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 29 Jan 2022]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

27 Jan 2022

[COVID-19 emergency operations center: experience of the Rio de Janeiro municipality, Brazil](#)

Brief communication | Portuguese |

Risk Analysis

Volume 41, Issue 12 Pages: 2177-2414 December 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 29 Jan 2022]

[No new digest content identified]

Science

Volume 375| Issue 6579| 28 Jan 2022

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science Translational Medicine

Volume 14| Issue 629| 26 Jan 2022

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Social Science & Medicine

Volume 292 January 2022

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/292/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 29 Jan 2022]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 42, issue 3-4, August 2021

<https://link.springer.com/journal/11017/volumes-and-issues/42-3>

Special Issue: A plea for an experimental philosophy of medicine

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 45 January–February 2022

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/45/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 27, Issue 1 Pages: i-iv, 1-119 January 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

SERIES ON ADOLESCENT HEALTH

[Reviewed earlier]

Vaccine

Volume 40, Issue 2 Pages 173-396 (21 January 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/2>

Discussion Abstract only

[Considering human challenge trials for tuberculosis vaccine development](#)

Gavriel Kleinwaks, Virginia Schmit, Josh Morrison

Pages 173-174

Discussion No access

[How can early stage economic evaluation help guide research for future vaccines?](#)

A.T. Newall, P. Beutels, H.W. Tuffaha, P.S. Hall, M. Jit

Pages 175-177

Review article Open access

[One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review](#)

Anar Andani, Pierre van Damme, Eveline M. Bunge, Fernanda Salgado, ... Bernard Hoet

Pages 196-205

Research article Full text access

[Willingness to vaccinate against SARS-CoV-2: The role of reasoning biases and conspiracist ideation](#)

Michael V. Bronstein, Erich Kummerfeld, Angus MacDonald, Sophia Vinogradov
Pages 213-222

Research article Open access

[Epidemiology of pertussis in Costa Rica and the impact of vaccination: A 58-year experience \(1961–2018\)](#)

María L. Avila-Agüero, Kattia Camacho-Badilla, Rolando Ulloa-Gutierrez, Carlos Espinal-Tejada, ...
James D. Cherry
Pages 223-228

Research article Full text access

[Predicting vaccine uptake during COVID-19 crisis: A motivational approach](#)

Mathias Schmitz, Olivier Luminet, Olivier Klein, Sofie Morbée, ... Maarten Vansteenkiste
Pages 288-297

Research article Open access

[Towards a population-based threshold of protection for COVID-19 vaccines](#)

David Goldblatt, Andrew Fiore-Gartland, Marina Johnson, Adam Hunt, ... Donna Ambrosino
Pages 306-315

Research article Abstract only

[Provider response and follow-up to parental declination of HPV vaccination](#)

Marjorie A. Margolis, Noel T. Brewer, Marcella H. Boynton, Jennifer Elston Lafata, ... Melissa B. Gilkey
Pages 344-350

Research article Open access

[The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study](#)

Carlotta Fack, Robin Wood, Mark Hatherill, Frank Cobelens, Sabine Hermans
Pages 364-369

Research article Open access

[National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study](#)

Jessica Price, Jessica Mooney, Carolyn Bain, John Tanko Bawa, ... William P. Hausdorff
Pages 370-379

Value in Health

January 2022 Volume 25 Issue 1 p1-160
<https://www.valueinhealthjournal.com/current>
[Reviewed earlier]

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 29 Jan 2022]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but [unpublished manuscripts](#) (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

Comparative effectiveness of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign

Theodore Lytras, Flora Kontopidou, Angeliki Lambrou, Sotirios Tsiodras

medRxiv 2022.01.28.22270009; doi: <https://doi.org/10.1101/2022.01.28.22270009>

Critical success factors for high routine immunization performance: A case study of Nepal

Kyra A Hester, Zoe Sakas, Anna S Ellis, Anindya Sekhar Bose, Roopa Darwar, Jhalak Gautam, Chandni Jaishwal, Hanleigh James, Pinar Keskinocak, Dima Nazzal, Emily Ogutu, Katie Rodriguez, Francisco Castillo Zunino, Sameer Dixit, Robert A. Bednarczyk, Matthew C Freeman, Vaccine Exemplars Research Consortium

medRxiv 2022.01.28.22270023; doi: <https://doi.org/10.1101/2022.01.28.22270023>

Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations

Brittany A Petros, Jacquelyn Turcinovic, Nicole Welch, Laura White, Eric Kolaczyk, Matthew Bauer, Michael Cleary, Sabrina Dobbins, Lynn Doucette-Stamm, Mitch Gore, Parvathy Nair, Tien Nguyen, Scott Rose, Bradford Taylor, Daniel Tsang, Erik Wendlandt, Michele Hope, Judy Platt, Karen Jacobson, Tara Bouton, Seyho Yune, Jared Auclair, Lena Landaverde, Catherine M. Klapperich, Davidson H Hamer, William P Hanage, Bronwyn MacInnis, Pardis Sabeti, John H Connor, Michael Springer

medRxiv 2022.01.27.22269787; doi: <https://doi.org/10.1101/2022.01.27.22269787>

Estimates of the impact on COVID-19 deaths of unequal global allocations of vaccines

John Paul Callan

medRxiv 2022.01.26.22269347; doi: <https://doi.org/10.1101/2022.01.26.22269347>

Is mandatory vaccination in population over 60 adequate to control the COVID-19 pandemic in E.U.?

Nikolaos Rachaniotis, Thomas Dasaklis, Filippas Fotopoulos, Michael Chouzouris, Thomas Georgiadis, Antigoni Lyberaki, Platon Tinios

medRxiv 2022.01.25.22269867; doi: <https://doi.org/10.1101/2022.01.25.22269867>

Critical success factors for high routine immunization performance: A case study of Senegal

Zoe Sakas, Kyra A. Hester, Katie Rodriguez, Saly Amos Diatta, Anna S. Ellis, Daouda Malick Gueye, Dawn Matapano, Pr Souleymane Mboup, Emily Awino Ogutu, Chenmua Yang, Robert A. Bednarczyk, Matthew C Freeman, Moussa Sarr, Vaccine Exemplars Research Consortium
medRxiv 2022.01.25.22269847; doi: <https://doi.org/10.1101/2022.01.25.22269847>

Omicron infection of vaccinated individuals enhances neutralizing immunity against the Delta variant

Khadija Khan, Farina Karim, Sandile Cele, James Emmanuel San, Gila Lustig, Houriiyah Tegally, Yuval Rosenberg, Mallory Bernstein, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, Nokuthula Ngcobo, Yoliswa Miya, Matilda Mazibuko, Ntombifuthi Mthabela, Zoey Mhlane, Nikiwe Mbatha, Jennifer Giandhari, Yajna Ramphal, Taryn Naidoo, Nithendra Manickchand, Nombulelo Magula, Salim Abdool Karim, Glenda Gray, Willem Hanekom, Anne von Gottberg, Ron Milo, Bernadett Gosnell, Richard Lessells, Tulio de Oliveira, Penny Moore, Yunus S Moosa, Alex Sigal
medRxiv 2021.12.27.21268439; doi: <https://doi.org/10.1101/2021.12.27.21268439>

COVID-19 vaccine attitude and its predictors among people living with chronic health conditions in Ibadan, Nigeria

Lucia Yetunde Ojewale, Rotimi Felix Afolabi, Adesola Ogunniyi
medRxiv 2022.01.27.22269947; doi: <https://doi.org/10.1101/2022.01.27.22269947>

The impacts of increased global vaccine sharing on the COVID-19 pandemic; a retrospective modelling study

Sam Moore, Edward M Hill, Louise J Dyson, Michael J Tildesley, Matt J Keeling
medRxiv 2022.01.26.22269877; doi: <https://doi.org/10.1101/2022.01.26.22269877>

Systematic review of social determinants of childhood immunisation in low- and middle-income countries and equity impact analysis of childhood vaccination coverage in Nigeria

Sarah V Williams, Tanimola Akande, Kaja Abbas
medRxiv 2022.01.24.22269771; doi: <https://doi.org/10.1101/2022.01.24.22269771>

South African Population Immunity and Severe Covid-19 with Omicron Variant

Shabir Madhi, Gaurav Kwatra, Jonathan E Myers, Waasila Jassat, Nisha Dhar, Christian K Mukendi, Amit Nana, Lucille Blumberg, Richard Welch, Nicoletta Ngorima-Mabhena, Portia C Mutevedzi
medRxiv 2021.12.20.21268096; doi: <https://doi.org/10.1101/2021.12.20.21268096>

Trust in the scientific research community predicts intent to comply with COVID-19 prevention measures: An analysis of a large-scale international survey dataset

Hyemin Han
medRxiv 2021.12.08.21267486; doi: <https://doi.org/10.1101/2021.12.08.21267486>

Wellcome Open Research [to 29 Jan 2022]
<https://wellcomeopenresearch.org/browse/articles>
[Accessed 29 Jan 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics

Revised

[A patient satisfaction survey and educational package to improve the care of people](#)

[hospitalised with COVID-19: a quality improvement project, Liverpool, UK](#) [version 2; peer review: 2 approved]

Muhammad Shamsher Ahmad, Scott Rory Hicks, Rebecca Watson, Rajia Akter Ahmed, Lewis Jones, Marcella Vaselli, Meng-San Wu, Fatima Hayat, Libuse Ratcliffe, Mark McKenna, Paul Hine, Sylviane Defres, Tom Wingfield

Peer Reviewers Katherine Ajdukiewicz; Vishesh Paul

Funder

Wellcome Trust

LATEST VERSION PUBLISHED 25 Jan 2022

Systematic Review metrics *AWAITING PEER REVIEW*

[The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions.](#) [version 1; peer review: awaiting peer review]

Alistair R.D. McLean, Sumayyah Rashan, Lien Tran, Lorenzo Arena, AbdulAzeez Lawal, Brittany J. Maguire, Sandra Adele, Emilia Sitsofe Antonio, Matthew Brack, Fiona Caldwell, Verena Iona Carrara, Reema Charles, Barbara Wanjiru Citarella, Terrence B. Epie, Vitalis Fambombi Feteh, Kalynn Kennon, Gerald Jamberi Makuka, Roland Ngu, Amen-Patrick Nwosu, Sopuruchukwu Obiesie, Chinwe Ogbonnaa-Njoku, Parvesh Paul, Caitlin Richmond, Sauman Singh-Phulgenda, Samantha Strudwick, Carina S.B. Tyrrell, Kasia Stepniewska, Nathalie Strub-Wourgaft, Nicholas J. White, Philippe J. Guérin

Peer Reviewers Invited

Funders

Wellcome

Bundesministerium für Bildung und Forschung, Germany

International Solidarity Service, Republic and Canton of Geneva

PUBLISHED 25 Jan 2022

Abstract

Background: Many available medicines have been evaluated as potential repurposed treatments for coronavirus disease 2019 (COVID-19). We summarise the registered study landscape for 32 priority pharmacological treatments identified following consultation with external experts of the COVID-19 Clinical Research Coalition.

Methods: All eligible trial registry records identified by systematic searches of the World Health Organisation International Clinical Trials Registry Platform as of 26th May 2021 were reviewed and extracted. A descriptive summary of study characteristics was performed.

Results: We identified 1,314 registered studies that included at least one of the 32 priority pharmacological interventions. The majority (1,043, 79%) were randomised controlled trials (RCTs). The sample size of the RCTs identified was typically small (median (25th, 75th percentile) sample size = 140 patients (70, 383)), i.e. individually powered only to show very large effects. The most extensively evaluated medicine was hydroxychloroquine (418 registered studies). Other widely studied interventions were convalescent plasma (n=208), ritonavir (n=189) usually combined with lopinavir (n=181), and azithromycin (n=147). Very few RCTs planned to recruit participants in low-income countries (n=14; 1.3%). A minority of studies (348, 26%) indicated a willingness to share individual

participant data. The living systematic review data are available at <https://iddo.cognitive.city>

Conclusions: There are many registered studies planning to evaluate available medicines as potential repurposed treatments of COVID-19. Most of these planned studies are small, and therefore substantially underpowered for most relevant endpoints. Very few are large enough to have any chance of providing enough convincing evidence to change policies and practices. The sharing of individual participant data (IPD) from these studies would allow pooled IPD meta-analyses which could generate definitive conclusions, but most registered studies did not indicate that they were willing to share their data.

* * * *

Think Tanks

Brookings [to 29 Jan 2022]

<http://www.brookings.edu/>

Accessed 29 Jan 2022

Coronavirus (COVID-19)

[When a universal coronavirus vaccine arrives, we should test payments for vaccine recipients](#)

Robert E. Litan

Wednesday, January 26, 2022

Africa in Focus

[Vaccine inequity: Ensuring Africa is not left out](#)

Michel Sidibé

Monday, January 24, 2022

Chatham House [to 29 Jan 2022]

<https://www.chathamhouse.org/>

Accessed 29 Jan 2022

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 29 Jan 2022

Upcoming Event

[Covid-19 Vaccine Confidence at One Year](#)

February 4, 2022

Podcast Episode

[Dr. Michael Osterholm: "Don't Be Surprised When You Are Surprised."](#)

January 28, 2022 | By H. Andrew Schwartz, J. Stephen Morrison

Report

[Innovative Data Collection Methods for International Development](#)

January 26, 2022 | By Daniel F. Runde, Romina Bandura

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 29 Jan 2022

January 28, 2022 *News Release*

42% of Adults, and 70% of Those Likely Booster-Eligible, Now Say They've Gotten a COVID-19 Booster Shot; The Share Who Received At Least One Dose Inches Up to 77% in Omicron's Wake

Black and Hispanic Adults are More Likely Than White Adults to Worry About Omicron's Effects, Including Becoming Seriously Ill or Missing Work Due to Infection The latest KFF COVID-19 Vaccine Monitor report shows that 42% of all adults nationwide have received a COVID-19 booster and more than three quarters (77%)...

January 26, 2022 *News Release*

Key Facts on Health and Health Care by Race and Ethnicity

With the COVID-19 pandemic impacting communities of color disproportionately in their health and economic well-being, long-term racial and ethnic disparities have received growing attention. But these inequities in our health system are not new and are a part of larger issues of systemic racism. An updated KFF chart pack analyzes...

* * * *

Contents [click to move among sections]

::

Milestones - Perspectives

:: *Coronavirus [COVID-19] - WHO*

:: *Emergencies*

:: *Organization Announcements*

:: *Journal Watch*

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*